Autopsy report · NCT05067972
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
Cause of deathFunding or business, also regulatory or ethics
“Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.”
Life of this trial
- Ran for about 2 years before it stopped.
- 30 participants enrolled.
- Results were posted on the registry 1 year 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Ovarian Neoplasms; Endometrial Neoplasms; Breast Neoplasms
- Interventions
- PF-07260437; B7-H4 IHC
- Participants
- 30
- Sites
- 15
- Countries
- Puerto Rico, United States
Trials that died the same way
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
“A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.” - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
“Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.” - A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
“The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.